Uploaded December 2025 | Updated November 2026, 7 hours ago
Presented By: Dr. Fred Parietti
Speaker Biography: Fred is the Co-founder and CEO of Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs. Founded in 2016, the company’s mission is to scale patient access to cell therapies and other individualized medicines.
Under Fred’s leadership, the company created the first cell therapy robotics system to be compatible with existing, market-leading GMP equipment. This means cell therapy manufacturers can scale without significantly changing their existing processes, minimizing process and regulatory risk. Additionally, Multiply Labs brought to market the first technology to manufacture individualized pharmaceutical capsules at industrial scale.
Fred holds a PhD in Mechanical Engineering from the Massachusetts Institute of Technology. He has co-authored 30+ peer-reviewed robotics publications and 12+ patents and patent applications, which have been cited more than 2,000 times. Prior to his research at MIT, Fred worked on robotics at Carnegie Mellon University, ETH Zurich, and Polytechnic University of Milan.
Webinar: Robotic Automation of Cell Isolation to Streamline Cell Therapy Manufacturing
Webinar Abstract: Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to scaling the manufacturing of these therapies. By standardizing critical workflows and operating seamlessly with GMP-compliant instruments, robots enable levels of throughput, reproducibility, and efficiency that were previously out of reach.
In this talk, Dr. Fred Parietti, co-founder and CEO of Multiply Labs, will share how robotic biomanufacturing clusters are redefining what’s possible inside the cleanroom. As a case study, he will highlight the integration of the GenScript CytoSinct™ 1000 into the Multiply Labs robotic platform. This fully automated cell isolation workflow demonstrates how robotics can deliver higher consistency, streamline operations, and shorten production timelines - all while operating with validated, industry-leading tools.
Attendees will learn how robotics improves the unit economics of cell therapy manufacturing, enables parallelism for higher throughput, and accelerates the automation process. More than incremental efficiency, this approach points to a new standard for scalable, automated cell therapy production.
Learning Objectives:
1. How robotics radically improves the unit economics of cell therapy manufacturing, increasing throughput, and accelerating timelines?
2. How the robotic system overcomes potential regulatory and process barriers by operating market-leading GMP instruments that are already deployed?
3. How can cell isolation be robotic automated utilizing GenScript CytoSinct and Multiply lab platform?
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-gene-therapy-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-gene-therapy-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 10/15/2026): (labroots.com/virtual-event/cell-gene-therapy-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Presented By: Dr. Fred Parietti
Speaker Biography: Fred is the Co-founder and CEO of Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs. Founded in 2016, the company’s mission is to scale patient access to cell therapies and other individualized medicines.
Under Fred’s leadership, the company created the first cell therapy robotics system to be compatible with existing, market-leading GMP equipment. This means cell therapy manufacturers can scale without significantly changing their existing processes, minimizing process and regulatory risk. Additionally, Multiply Labs brought to market the first technology to manufacture individualized pharmaceutical capsules at industrial scale.
Fred holds a PhD in Mechanical Engineering from the Massachusetts Institute of Technology. He has co-authored 30+ peer-reviewed robotics publications and 12+ patents and patent applications, which have been cited more than 2,000 times. Prior to his research at MIT, Fred worked on robotics at Carnegie Mellon University, ETH Zurich, and Polytechnic University of Milan.
Webinar: Robotic Automation of Cell Isolation to Streamline Cell Therapy Manufacturing
Webinar Abstract: Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to scaling the manufacturing of these therapies. By standardizing critical workflows and operating seamlessly with GMP-compliant instruments, robots enable levels of throughput, reproducibility, and efficiency that were previously out of reach.
In this talk, Dr. Fred Parietti, co-founder and CEO of Multiply Labs, will share how robotic biomanufacturing clusters are redefining what’s possible inside the cleanroom. As a case study, he will highlight the integration of the GenScript CytoSinct™ 1000 into the Multiply Labs robotic platform. This fully automated cell isolation workflow demonstrates how robotics can deliver higher consistency, streamline operations, and shorten production timelines - all while operating with validated, industry-leading tools.
Attendees will learn how robotics improves the unit economics of cell therapy manufacturing, enables parallelism for higher throughput, and accelerates the automation process. More than incremental efficiency, this approach points to a new standard for scalable, automated cell therapy production.
Learning Objectives:
1. How robotics radically improves the unit economics of cell therapy manufacturing, increasing throughput, and accelerating timelines?
2. How the robotic system overcomes potential regulatory and process barriers by operating market-leading GMP instruments that are already deployed?
3. How can cell isolation be robotic automated utilizing GenScript CytoSinct and Multiply lab platform?
Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-gene-therapy-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-gene-therapy-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 10/15/2026): (labroots.com/virtual-event/cell-gene-therapy-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc










